Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis

医学 狼疮性肾炎 免疫学 系统性红斑狼疮 内科学 疾病
作者
Jingjing Jin,Meng Tan,Ying Cong Ryan Shea Tan,Ming‐Hui Zhao
出处
期刊:Nephrology Dialysis Transplantation [Oxford University Press]
卷期号:40 (9): 1775-1785 被引量:12
标识
DOI:10.1093/ndt/gfaf049
摘要

BACKGROUND: This study aimed to evaluate the efficacy and safety of telitacicept for the treatment of lupus nephritis (LN) in real-world clinical practice. METHODS: Adult patients with LN receiving additional telitacicept at 80/160 mg once per week were recruited, while patients receiving only standard therapy were included as the control group using a 1:1 propensity score-matching approach. The primary outcomes were the proportions of patients achieving complete renal response (CRR) and primary efficacy renal response (PERR). RESULTS: Forty-four patients in both the control and telitacicept groups were enrolled, with median follow-up periods of 10.78 ± 3.37 and 10.5 ± 3.78 months, respectively. Compared with the control group, a significant improvement was observed in the proportion of patients achieving CRR (11.36% vs 29.55%, P = .034) and PERR (45.45% vs 68.18%, P = .031) in the telitacicept group at the last visit. Median proteinuria was reduced by 0.97 g/day (63.82%) from baseline in the telitacicept group, compared with a reduction of 0.31 g/day (25.31%) in the control group. Additionally, the telitacicept group showed notable treatment responses in the median SLE Disease Activity Index-2000 score, Physician's Global Assessment score and glucocorticoid dose reduction. Subgroup analysis revealed that telitacicept exhibited a more prominent therapeutic effect in patients with type V LN and those with proteinuria exceeding 3 g/day. Telitacicept was well tolerated, and the incidence of adverse events was similar between the two groups. CONCLUSIONS: LN patients receiving additional telitacicept treatment demonstrated better disease remission, particularly in those with type V LN and proteinuria ≥3 g/day, with a favorable safety profile in real-world clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Eternity完成签到,获得积分10
刚刚
天天快乐的应助被Jase采纳,获得10
1秒前
津津完成签到,获得积分10
1秒前
yosh发布了新的文献求助10
1秒前
十一完成签到 ,获得积分10
1秒前
jie发布了新的文献求助10
2秒前
莓莓发布了新的文献求助10
2秒前
冰棍发布了新的文献求助10
2秒前
苁蓉远志完成签到 ,获得积分10
2秒前
molihuakai的应助被白春蕾采纳,获得10
3秒前
3秒前
MIN完成签到,获得积分10
4秒前
狮子发布了新的文献求助10
4秒前
NOIR4LU完成签到 ,获得积分10
4秒前
一谷完成签到 ,获得积分10
4秒前
白XX发布了新的文献求助10
5秒前
xyt完成签到 ,获得积分10
5秒前
6秒前
molihuakai的应助被想人陪的蚂蚁采纳,获得10
6秒前
Lu丶L完成签到,获得积分10
6秒前
7秒前
7秒前
KMS完成签到,获得积分10
8秒前
moon发布了新的文献求助10
8秒前
8秒前
白芷完成签到,获得积分10
8秒前
Luna完成签到 ,获得积分10
10秒前
晓天发布了新的文献求助10
10秒前
10秒前
Jasper的应助被璐璐采纳,获得10
10秒前
桐桐的应助被冰棍采纳,获得10
10秒前
桐桐的应助被冰棍采纳,获得10
11秒前
JamesPei的应助被姜OMG采纳,获得10
11秒前
琪琪完成签到 ,获得积分10
11秒前
小波儿发布了新的文献求助10
11秒前
唐唐发布了新的文献求助10
11秒前
12秒前
12秒前
领导范儿的应助被困告采纳,获得10
14秒前
斯多姆发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527